AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2
Administration, Oral
Animals
Antiviral Agents
/ pharmacology
COVID-19
/ virology
Cell Line
Cell Line, Tumor
Chlorocebus aethiops
Coronavirus 229E, Human
/ metabolism
Coronavirus OC43, Human
/ metabolism
Cricetinae
Epithelial Cells
/ virology
Guanosine
/ pharmacology
Guanosine Monophosphate
/ analogs & derivatives
Humans
Lung
/ virology
Phosphoramides
/ pharmacology
Prodrugs
/ pharmacology
SARS-CoV-2
/ drug effects
Vero Cells
Virus Replication
/ drug effects
COVID-19 Drug Treatment
AT-511
AT-527
AT-9010
COVID-19
SARS-CoV-2
lung
triphosphate
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
18 03 2021
18 03 2021
Historique:
received:
25
11
2020
accepted:
03
02
2021
pubmed:
10
2
2021
medline:
2
4
2021
entrez:
9
2
2021
Statut:
epublish
Résumé
The impact of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19, is global and unprecedented. Although remdesivir has recently been approved by the FDA to treat SARS-CoV-2 infection, no oral antiviral is available for outpatient treatment. AT-527, an orally administered double prodrug of a guanosine nucleotide analog, was previously shown to be highly efficacious and well tolerated in hepatitis C virus (HCV)-infected subjects. Here, we report the potent
Identifiants
pubmed: 33558299
pii: AAC.02479-20
doi: 10.1128/AAC.02479-20
pmc: PMC8097421
pii:
doi:
Substances chimiques
AT-511
0
Antiviral Agents
0
Phosphoramides
0
Prodrugs
0
Guanosine
12133JR80S
Guanosine Monophosphate
85-32-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2021 Good et al.
Références
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):E162-E171
pubmed: 29279395
ACS Cent Sci. 2020 May 27;6(5):672-683
pubmed: 32483554
J Med Virol. 2020 Jun;92(6):546-547
pubmed: 32115732
J Virol Methods. 2017 Aug;246:51-57
pubmed: 28359770
J Virol Methods. 1988 Aug;20(4):309-21
pubmed: 2460479
Am Rev Respir Dis. 1982 Aug;126(2):332-7
pubmed: 7103258
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
Science. 2020 May 15;368(6492):779-782
pubmed: 32277040
AAPS J. 2018 Oct 8;20(6):107
pubmed: 30298434
Antimicrob Agents Chemother. 2019 Sep 30;:
pubmed: 31570394
Antimicrob Agents Chemother. 2020 Jul 22;64(8):
pubmed: 32513797
J Virol Methods. 1990 Apr;28(1):101-6
pubmed: 2161417
Virol J. 2016 Feb 06;13:24
pubmed: 26852031
Nucleic Acids Res. 2015 Sep 30;43(17):8416-34
pubmed: 26304538
Eur Respir J. 2020 Apr 16;55(4):
pubmed: 32269085
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
PLoS One. 2020 Jan 8;15(1):e0227104
pubmed: 31914458
Nat Protoc. 2008;3(7):1125-31
pubmed: 18600217
Virus Res. 2017 Apr 15;234:58-73
pubmed: 28174054
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):E3900-9
pubmed: 25197083